Oncolytic Virotherapy

About Vyriad

Vyriad is a private, clinical-stage biotech developing a suite of targeted viral delivery platforms for genetic medicines and oncolytic virotherapy. Founded by Mayo Clinic scientists, the company leverages deep expertise in viral engineering, particularly with vesicular stomatitis virus (VSV) and measles virus backbones, to create therapies that directly target cells in the body. With active clinical trials in oncology and a partnership-driven business model, Vyriad aims to de-risk and advance novel treatments from preclinical development through manufacturing and early-phase clinical testing.

Therapeutic Areas